Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20:2959–70.

Article  CAS  PubMed  Google Scholar 

Kuzuya T, Kawabe N, Ariga M, et al. Clinical outcomes of cabozantinib in patients previously treated with atezolizumab/bevacizumab for advanced hepatocellular carcinoma—importance of good liver function and good performance status. Cancers. 2023;15:2952.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan SL, Ryoo BY, Mo F, et al. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. J Hepatol. 2024;81:258–64.

Article  CAS  PubMed  Google Scholar 

Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nagashima S, Kobayashi S, Tsunoda S, et al. A case of complete remission by cabozantinib as an end-line treatment for advanced hepatocellular carcinoma. Clin J Gastroenterol. 2025;18:125–9.

Article  PubMed  Google Scholar 

Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:995–1008.

Article  CAS  PubMed  Google Scholar 

Yamamoto M, Terashima T, Yamashita T, et al. Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification. Hepatol Res. 2024;54:315–9.

Article  CAS  PubMed  Google Scholar 

Sang YB, Kim G, Hwang S, et al. Dramatic response to cabozantinib in a patient with refractory hepatocellular carcinoma with c-MET amplification. J Clin Transl Hepatol. 2023;11:747–50.

PubMed  Google Scholar 

Mahn R, Sadeghlar F, Bartels A, et al. Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report with long term follow-up outcomes. Medicine (Baltimore). 2021;100:e27082.

Article  PubMed  PubMed Central  Google Scholar 

Yang X, Shi J, Chen X, et al. Efficacy of cabozantinib and nivolumab in treating hepatocellular carcinoma with RET amplification, high tumor mutational burden, and PD-L1 expression. Oncologist. 2020;25:470–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kondo S, Ojima H, Tsuda H, et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol. 2013;18:207–13.

Article  CAS  PubMed  Google Scholar 

Wang H, Rao B, Lou J, et al. The function of the HGF/c-Met axis in hepatocellular carcinoma. Front Cell Dev Biol. 2020;8:55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Z, Suda G, Maehara O, et al. Changes in serum growth factors during lenvatinib predict the post progressive survival in patients with unresectable hepatocellular carcinoma. Cancers (Basel). 2022;14:232.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aoki T, Kudo M, Ueshima K, et al. Exploratory analysis of lenvatinib therapy in patients with unresectable hepatocellular carcinoma who have failed prior PD-1/PD-L1 checkpoint blockade. Cancers (Basel). 2020;12(10):3048.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3:e59125.

Article  PubMed  PubMed Central  Google Scholar 

Tomonari T, Tani J, Ogawa C, et al. Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma. Hepatol Res. 2023;53:172–8.

Article  CAS  PubMed  Google Scholar 

Okubo H, Ando H, Nakamura S, et al. Real world data of cabozantinib in patients with hepatocellular carcinoma: focusing on dose setting and modification. Cancer Med. 2024;13:e70222.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lacy SA, Miles DR, Nguyen LT. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin Pharmacokinet. 2017;56:477–91.

Article  PubMed  Google Scholar 

Okubo H, Ando H, Takasaki Y, et al. Impact of cabozantinib exposure on proteinuria and muscle toxicity in patients with unresectable hepatocellular carcinoma. Pharmaceuticals (Basel). 2022;15:146.

Article  Google Scholar